... biotechnology company, today announced that preclinical data demonstrating the sensitivity of triple negative breast cancer (TNBC) cell lines to PCM-075, its highly selective Polo-like kinase 1 (PLK1) Inhibitor, will be featured as a Poster Presentation at the 40th San Antonio Breast Cancer…
News
- Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines ...
- Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in ...
BOTHELL, WA, USA I December 7, 2017 I Seattle Genetics, Inc. (NASDAQ: SGEN) today announced updated data from an ongoing phase 1 clinical trial evaluating ladiratuzumab vedotin in patients with metastatic triple negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium…
- Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended ...
LOS ANGELES, CA, USA I December 6, 2017 I Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in…
- SA biotech gains critical entry into European market
The San Antonio-based biotech company struck an agreement with a British company to market and distribute its stem cell products in the United Kingdom and in Western Europe. The deal with Caltag Medsystems Ltd. will initially involve StemBioSys' cell expansion products. But as StemBioSys…
- 'Most vulnerable' dying in 'America's Finest City'
More than 400 makeshift shelters sprung up downtown, covering sidewalks across from new high-rise apartment buildings that have climbed in lockstep with the booming biotech-heavy economy and soaring rents, among the nation's highest. A studio apartment goes for around $1,500 a month, ...…